Part 2: Drug Interactions Involving Cannabis Products in Persons Aged 18 and Over: A Summary of Published Case Reports and Analysis of the FDA Adverse Event Reporting System
Abstract The increasing utilization of cannabis products combined with lack of data regarding potential cannabis–prescription drug interactions is concerning. This…
